Bioqual, Inc.
BIOQ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$27.73M
Close$
$13.84
55.3% downside
Current Fair Value
55.3% downsideOvervalued by 55.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $27.73 Million |
|---|---|
| Enterprise Value | $49.75 Million |
| Earnings per Share | $-4.66 |
| Beta | -0.09 |
| Outstanding Shares | 894,416 |
Return
| Return on Equity | -13.62% |
|---|---|
| Return on Assets | -6.45% |
| Return on Invested Capital | -7.29% |
Valuation & Multiples
| P/E Ratio | -6.29 |
|---|---|
| PEG | -6.36 |
| Price to Sales | 0.7 |
| Price to Book Ratio | 0.86 |
| Enterprise Value to Revenue | 1.24 |
| Enterprise Value to EBIT | -10.99 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.67 |
| Debt to Equity | 1.02 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 22, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Bioqual, Inc.
278 employees
CEO: Hanne Andersen-Elyard
Bioqual, Inc. delivers a range of preclinical research solutions, encompassing both in-vivo and in-vitro methodologies, to its diverse clientele of commercial enterprises and government agencies across the United States. Their expertise ...